Stephen B. Willingham

9.4k total citations · 3 hit papers
43 papers, 5.5k citations indexed

About

Stephen B. Willingham is a scholar working on Immunology, Molecular Biology and Physiology. According to data from OpenAlex, Stephen B. Willingham has authored 43 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 16 papers in Molecular Biology and 13 papers in Physiology. Recurrent topics in Stephen B. Willingham's work include Adenosine and Purinergic Signaling (13 papers), Phagocytosis and Immune Regulation (11 papers) and Inflammasome and immune disorders (9 papers). Stephen B. Willingham is often cited by papers focused on Adenosine and Purinergic Signaling (13 papers), Phagocytosis and Immune Regulation (11 papers) and Inflammasome and immune disorders (9 papers). Stephen B. Willingham collaborates with scholars based in United States, Germany and India. Stephen B. Willingham's co-authors include Jenny P.‐Y. Ting, Dan T. Bergstralh, Irving L. Weissman, Joseph A. Duncan, Fabio Re, Kipp Weiskopf, Ravindra Majeti, Max T. Huang, Mark P. Chao and Jens Volkmer and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Stephen B. Willingham

41 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47

2010 594 citations Mark P. Chao, Ash A. Alizadeh et al. profile →
Cutting Edge: Inflammasome Activation by Alum and Alum’s Adjuvant Effect Are Mediated by NLRP3

2008 510 citations Stephen B. Willingham, Jenny P.‐Y. Ting et al. The Journal of Immunology profile →
Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

2013 506 citations Jens-Peter Volkmer, Stephen B. Willingham et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen B. Willingham United States	23	3.1k	2.5k	1.1k	536	514	43	5.5k
Anthony Rongvaux United States	32	3.2k 1.0×	2.7k 1.1×	1.2k 1.1×	473 0.9×	321 0.6×	51	6.5k
Oscar R. Colegio United States	23	2.8k 0.9×	3.0k 1.2×	1.1k 1.1×	345 0.6×	448 0.9×	47	6.5k
Santos Mañes Spain	46	2.5k 0.8×	3.2k 1.2×	1.7k 1.6×	433 0.8×	362 0.7×	88	6.9k
Jonathan D. Curtis United States	14	5.1k 1.7×	2.8k 1.1×	2.3k 2.2×	460 0.9×	395 0.8×	15	8.1k
Anna Mondino Italy	39	3.8k 1.2×	2.2k 0.9×	1.9k 1.8×	317 0.6×	327 0.6×	109	6.6k
Kenneth A. Frauwirth United States	22	4.3k 1.4×	1.8k 0.7×	2.1k 2.0×	313 0.6×	331 0.6×	29	6.6k
Li‐Fan Lu United States	38	6.0k 2.0×	3.4k 1.3×	2.0k 1.9×	462 0.9×	400 0.8×	63	9.9k
Camilla Jandus Switzerland	34	3.3k 1.1×	1.6k 0.6×	1.4k 1.4×	206 0.4×	415 0.8×	82	4.7k
Natalio Garbi Germany	45	5.2k 1.7×	1.5k 0.6×	2.3k 2.2×	407 0.8×	519 1.0×	83	7.5k
Amanda C. Poholek United States	30	4.2k 1.4×	1.3k 0.5×	1.4k 1.3×	285 0.5×	273 0.5×	49	5.9k

Countries citing papers authored by Stephen B. Willingham

Since Specialization

Citations

This map shows the geographic impact of Stephen B. Willingham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen B. Willingham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen B. Willingham more than expected).

Fields of papers citing papers by Stephen B. Willingham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen B. Willingham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen B. Willingham. The network helps show where Stephen B. Willingham may publish in the future.

Co-authorship network of co-authors of Stephen B. Willingham

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen B. Willingham. A scholar is included among the top collaborators of Stephen B. Willingham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen B. Willingham. Stephen B. Willingham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Banuelos, Allison, Dongdong Feng, Kevin S. Kao, et al.. (2021). Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proceedings of the National Academy of Sciences. 118(29). 95 indexed citations

2.

Willingham, Stephen B., Andrew Hotson, & Richard A. Miller. (2020). Targeting the A2AR in cancer; early lessons from the clinic. Current Opinion in Pharmacology. 53. 126–133. 37 indexed citations

3.

Bergstralh, Dan T., Stephen B. Willingham, Christopher Thomas, et al.. (2020). Neisseria gonorrhoeae Activates the Proteinase Cathepsin B to Mediate the Signaling Activities of the NLRP3 and ASC-Containing Inflammasome. UNC Libraries. 4 indexed citations

4.

Willingham, Stephen B., Po Y. Ho, Andrew Hotson, et al.. (2018). A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models. Cancer Immunology Research. 6(10). 1136–1149. 162 indexed citations

5.

Betancur, Paola, Brian J. Abraham, Ying Ying Yiu, et al.. (2017). A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nature. 1 indexed citations

6.

Willingham, Stephen B., Andrew Hotson, Po Y. Ho, et al.. (2017). Abstract 5593: Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies. Cancer Research. 77(13_Supplement). 5593–5593. 1 indexed citations

7.

Betancur, Paola, Brian J. Abraham, Ying Ying Yiu, et al.. (2017). A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nature Communications. 8(1). 14802–14802. 178 indexed citations

8.

Willingham, Stephen B., Po Y. Ho, Robert D. Leone, et al.. (2016). Adenosine A2A receptor antagonist, CPI-444, blocks adenosine-mediated T cell suppression and exhibits anti-tumor activity alone and in combination with anti-PD-1 and anti-PD-L1. Annals of Oncology. 27. vi366–vi366. 2 indexed citations

9.

McCaffery, Ian, Ginna G. Laport, Andrew Hotson, et al.. (2016). Biomarker and clinical activity of CPI-444, a novel small molecule inhibitor of A2A receptor (A2AR), in a Ph1b study in advanced cancers. Annals of Oncology. 27. vi124–vi124. 6 indexed citations

10.

Liu, Jie, Lijuan Wang, Feifei Zhao, et al.. (2015). Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. PLoS ONE. 10(9). e0137345–e0137345. 381 indexed citations

11.

Huang, Wei, Jiwon Seo, Stephen B. Willingham, et al.. (2014). Learning from Host-Defense Peptides: Cationic, Amphipathic Peptoids with Potent Anticancer Activity. PLoS ONE. 9(2). e90397–e90397. 68 indexed citations

12.

Volkmer, Jens-Peter, Debashis Sahoo, Robert Chin, et al.. (2012). Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proceedings of the National Academy of Sciences. 109(6). 2078–2083. 187 indexed citations

13.

Kim, Donghee, et al.. (2012). Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia. 26(12). 2538–2545. 180 indexed citations

14.

Edris, Badreddin, Kipp Weiskopf, Anne Kathrin Volkmer, et al.. (2012). Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proceedings of the National Academy of Sciences. 109(17). 6656–6661. 211 indexed citations

15.

Duncan, Joseph A., Xi Gao, Max T. Huang, et al.. (2009). Neisseria gonorrhoeae Activates the Proteinase Cathepsin B to Mediate the Signaling Activities of the NLRP3 and ASC-Containing Inflammasome. The Journal of Immunology. 182(10). 6460–6469. 213 indexed citations

16.

Huang, Max T., Debra J. Taxman, Elizabeth Holley-Guthrie, et al.. (2009). Critical Role of Apoptotic Speck Protein Containing a Caspase Recruitment Domain (ASC) and NLRP3 in Causing Necrosis and ASC Speck Formation Induced by Porphyromonas gingivalis in Human Cells. The Journal of Immunology. 182(4). 2395–2404. 63 indexed citations

17.

Willingham, Stephen B., et al.. (2008). Cutting Edge: Inflammasome Activation by Alum and Alum’s Adjuvant Effect Are Mediated by NLRP3. The Journal of Immunology. 181(1). 17–21. 510 indexed citations breakdown →

18.

Ting, Jenny P.‐Y., Stephen B. Willingham, & Dan T. Bergstralh. (2008). NLRs at the intersection of cell death and immunity. Nature reviews. Immunology. 8(5). 372–379. 286 indexed citations

19.

Willingham, Stephen B., Dan T. Bergstralh, William O’Connor, et al.. (2007). Microbial Pathogen-Induced Necrotic Cell Death Mediated by the Inflammasome Components CIAS1/Cryopyrin/NLRP3 and ASC. Cell Host & Microbe. 2(3). 147–159. 234 indexed citations

20.

Willingham, Stephen B., Tiago F. Outeiro, Michael J. DeVit, Susan Lindquist, & Paul J. Muchowski. (2003). Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein. Science. 302(5651). 1769–1772. 328 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact